JP2024507118A5 - - Google Patents

Info

Publication number
JP2024507118A5
JP2024507118A5 JP2023547794A JP2023547794A JP2024507118A5 JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5 JP 2023547794 A JP2023547794 A JP 2023547794A JP 2023547794 A JP2023547794 A JP 2023547794A JP 2024507118 A5 JP2024507118 A5 JP 2024507118A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
mol
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507118A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016229 external-priority patent/WO2022174114A1/en
Publication of JP2024507118A publication Critical patent/JP2024507118A/ja
Publication of JP2024507118A5 publication Critical patent/JP2024507118A5/ja
Pending legal-status Critical Current

Links

JP2023547794A 2021-02-11 2022-02-11 抗トランスフェリン受容体融合タンパク質及びその使用方法 Pending JP2024507118A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148543P 2021-02-11 2021-02-11
US63/148,543 2021-02-11
PCT/US2022/016229 WO2022174114A1 (en) 2021-02-11 2022-02-11 Anti-transferrin receptor fusion proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024507118A JP2024507118A (ja) 2024-02-16
JP2024507118A5 true JP2024507118A5 (cg-RX-API-DMAC7.html) 2025-02-18

Family

ID=82837358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547794A Pending JP2024507118A (ja) 2021-02-11 2022-02-11 抗トランスフェリン受容体融合タンパク質及びその使用方法

Country Status (6)

Country Link
US (3) US20240148866A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291246A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507118A (cg-RX-API-DMAC7.html)
CN (1) CN116997364A (cg-RX-API-DMAC7.html)
MA (1) MA71665A (cg-RX-API-DMAC7.html)
WO (1) WO2022174114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71665A (fr) 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
TW202432602A (zh) 2022-12-05 2024-08-16 法商賽諾菲公司 運鐵蛋白受體結合蛋白
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Fc融合タンパク質の精製方法
JP6616189B2 (ja) * 2013-12-25 2019-12-04 Jcrファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
BR112020005271A2 (pt) * 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸-2-スルファターゼ免疫グロブリン融合タンパク質の精製
MA71665A (fr) 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
JP7789871B2 (ja) グルカゴン様ペプチド1受容体アゴニストおよびそれらの使用
JP2023517236A5 (cg-RX-API-DMAC7.html)
KR101949891B1 (ko) C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
JP6672533B1 (ja) C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法
US20250109191A1 (en) Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitor
EP3337828B1 (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EP2994489A2 (en) Anti-glucagon receptor antibodies and methods of use thereof
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
KR20180084045A (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
JP2024532426A5 (cg-RX-API-DMAC7.html)
JP7809067B2 (ja) 抗セラミド抗体
TWI808963B (zh) 使用人類化抗cxcr5抗體治療狼瘡
CN120693172A (zh) 用于治疗补体介导的疾病的与因子h融合的抗c5抗体
US20250134988A1 (en) Pan-Coronavirus Immunogenic Compositions
CN114127108A (zh) Il-17拮抗剂治疗自身免疫疾病的方法
US20220332822A1 (en) Subcutaneous administration of antibodies for the treatment of disease
WO2026072993A1 (en) Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
TW202535461A (zh) 使用抗sirpa抗體治療肝臟疾病或病症
CN117866092A (zh) 抗人cd73抗体或其抗原结合片段及其应用
CN116457370A (zh) 包含抗原和其醣工程化抗体的免疫组合物